AUPH
Aurinia Pharmaceuticals Inc.
NASDAQ · CAHealthcareBiotechnology
$15.25-4.45%
Price as of Jul 20, 2026
AUPH financials
Aurinia Pharmaceuticals Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $283.1M | $235.1M | $175.5M | $134.0M |
| Cost of revenue | $32.7M | $28.2M | $14.1M | $5.7M |
| Gross profit | $250.4M | $206.9M | $161.4M | $128.4M |
| Operating expenses | $145.5M | $211.6M | $253.1M | $239.8M |
| Operating income | $104.9M | -$4.7M | -$91.7M | -$111.5M |
| Net income | $287.2M | $5.8M | -$78.0M | -$108.2M |
| EBITDA | $127.8M | $31.7M | -$63.0M | -$103.6M |
| Basic EPS | $2.14 | $0.04 | $-0.54 | $-0.76 |
| Diluted EPS | $2.07 | $0.04 | $-0.54 | $-0.76 |
| Balance sheet | ||||
| Cash & equivalents | $80.2M | $83.4M | $48.9M | $94.2M |
| Total assets | $751.6M | $550.6M | $548.1M | $470.9M |
| Total liabilities | $170.3M | $173.2M | $170.1M | $65.4M |
| Stockholders’ equity | $581.3M | $377.5M | $378.0M | $405.4M |
| Total debt | $74.8M | $79.4M | $97.6M | $8.1M |
| Net debt | -$5.4M | -$4.1M | $48.7M | -$86.1M |
| Cash flow | ||||
| Operating cash flow | $135.7M | $44.4M | -$33.5M | -$79.5M |
| Capital expenditure | -$252.0K | -$281.0K | -$718.0K | -$292.0K |
| Free cash flow | $135.4M | $44.1M | -$34.2M | -$79.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$98.2M | -$40.2M | $0.00 | $0.00 |